Pulmonary hypertension (PH) is often associated with chronic kidney disease (CKD). “Pulmonary hypertension happens when the pressure in the blood vessels leading from the heart to the lungs is too high. With pulmonary hypertension, the blood vessels to the lungs develop an increased amount of muscle in the wall of the blood vessels.”
Dysfunction of the kidneys can result from the increased pressure that is central to pulmonary hypertension. Vein congestion increases along with the number of cytokines (signaling proteins that regulate individual cells), further damaging the kidneys.
Thus, “researchers of a new study have outlined considerations and management strategies for patients with pulmonary hypertension (PH) undergoing kidney transplantation resulting from chronic kidney disease, a condition increasingly related to certain types of PH.”
The most important consideration for a patient is to determine which PH group they belong to. This will determine the appropriate targeted therapy. Kidney disease primarily is associated with Group 5. This provides important information for transplantation (before and after). “Echocardiograms—recommended at 3 months post transplant to determine pulmonary pressures—can be repeated every year or every other year if there is a history of elevated pulmonary pressures.”
“Patients with connective tissue disease-associated PAH have the highest rates of kidney impairment, although kidney dysfunction is also a feature of other PH forms. Older age, high systemic blood pressure, diabetes, and increased right atrial pressure seem to be associated with kidney impairment in PH patients.”
Those patients with kidney disease and PH have several treatment options:
Dialysis is recommended for patients in Group 2. For those in Group 3, oxygen therapy may be critical. For patients in Group 4, anticoagulation and thrombectomy are the suggested treatments.
Pulmonary hypertension (PH) is often associated with chronic kidney disease (CKD). “Pulmonary hypertension happens when the pressure in the blood vessels leading from the heart to the lungs is too high. With pulmonary hypertension, the blood vessels to the lungs develop an increased amount of muscle in the wall of the blood vessels.”
Dysfunction of the kidneys can result from the increased pressure that is central to pulmonary hypertension. Vein congestion increases along with the number of cytokines (signaling proteins that regulate individual cells), further damaging the kidneys.
Thus, “researchers of a new study have outlined considerations and management strategies for patients with pulmonary hypertension (PH) undergoing kidney transplantation resulting from chronic kidney disease, a condition increasingly related to certain types of PH.”
The most important consideration for a patient is to determine which PH group they belong to. This will determine the appropriate targeted therapy. Kidney disease primarily is associated with Group 5. This provides important information for transplantation (before and after). “Echocardiograms—recommended at 3 months post transplant to determine pulmonary pressures—can be repeated every year or every other year if there is a history of elevated pulmonary pressures.”
“Patients with connective tissue disease-associated PAH have the highest rates of kidney impairment, although kidney dysfunction is also a feature of other PH forms. Older age, high systemic blood pressure, diabetes, and increased right atrial pressure seem to be associated with kidney impairment in PH patients.”
Those patients with kidney disease and PH have several treatment options:
Dialysis is recommended for patients in Group 2. For those in Group 3, oxygen therapy may be critical. For patients in Group 4, anticoagulation and thrombectomy are the suggested treatments.
about the author
Lisa Foster
Lisa Foster is a mom of 3 daughters, a puzzle lover, writer and HealthTree advocate. She believes in the mission of the foundation and the team that builds it forward. She calls Houston, Texas home.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.